- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01757587
Galvus (Vildagliptin) vs Placebo in Combination With Metformin and Insulin
Evaluation of Galvus (Vildagliptin) Efficacy Versus Placebo in Patients With Type 2 Diabetes, Inadequately Controlled by Metformin and Basal Insulin, This One Having Been Properly Titrated.
The main objective is to show that the addition of Galvus versus placebo in patients with type 2 diabetes treated with metformin (at the maximum tolerated dose) and basal insulin properly titrated, allows a greater proportion of patients achieving an HbA1c below 7%.
The primary efficacy endpoint was the percentage of patients responding to treatment (HbA1c less than 7%) after 3 months of treatment with Galvus or placebo
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
- Visit V1 : screening
Inclusion visit V2: Be verified inclusion criteria of patient. At the inclusion visit will be collected:
- Informed consent to participate in the study…
- The following data: age, duration of diabetes, usual basal insulin dose, other co-morbidities : hypertension, complications of diabetes, dyslipidemia, smoking (and their associated treatments).
- Data from physical examination and in particular: weight, BMI, waist circumference, systolic blood pressure (SBP) and diastolic (DBP)
- Therapeutic adjustments can be made. In the case of inefficient combination with a sulphonylurea (HbA1c> 7%), it will be stopped and basal insulin will be titrated during the run- in period (2 months) in order to obtain a good control of fasting glucose.
- Visit V3 : At the randomization visit, be collected the results of HbA1c and other biological assessment (FPG, fasting lipid profile). Moreover, the insulin will be collected and the patient will receive the treatment for 3 months (for ex Galvus in this case according to randomisation).
- Visit V4a the glycemic holter will be introduced and removed 5 days later (at visit V4B). The interstitial glucose will be calibrated during the Holter by the blood glucose. When collecting the glycemic holter, patients will also have a clinical examination and a new biological assessment (HbA1c, FPG, C peptide, fasting lipids ...) and an assessment of their dietary intake during the port the holter (overall calorie intake: cal + G, L, P)
- Visit V5 : the patient will receive the treatment for 3 months (placebo at this visit according the example cited above ).
- Visit V6A, it will be the same as for the visit V4a, the glycemic holter will be introduced and removed at V6B visit. Similarly, in the collection of glycemic holter, patients will also have a new clinical examination, laboratory evaluation (HbA1c, FPG, fasting lipids ...) and a dietary assessment (overall calorie intake: cal + G, L, P).
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Evry, France, 91000
- CH SUd Francilien
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients treated for at least 3 months with metformin (at the maximum tolerated dose (for at least 1 month) + / - sulfamide and basal insulin
- Patient with an HbA1c between 7 and 9% at the inclusion visit
- Patients able to use a continuous glucose monitoring system,
Exclusion Criteria:
- Patients already receiving a specific treatment of postprandial (GLP1, ..)
- Patients with type 1 diabetes, or secondary diabetes
- Patients with eating disorders
- Patients with major complications of diabetes
- Patients participating in another clinical trial
- Pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
50mg 2 tablets / day on 3 months, both periods of treatment
Other Names:
|
Active Comparator: Vildagliptin
|
50 mg, 2 tablets/day on 3 months, both periods of treatment
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of patients responding to treatment (HbA1c less than 7%)
Time Frame: after 3 months of treatment with Galvus or placebo
|
after 3 months of treatment with Galvus or placebo
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Compare HbA1c and other clinical and laboratory parameters (fasting plasma glucose (FPG), fasting lipids, weight)
Time Frame: after 3 months of treatment with Galvus or placebo
|
after 3 months of treatment with Galvus or placebo
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate more precisely the optimized glycemic control through a glycemic holter
Time Frame: after 3 months of treatment with Galvus or placebo
|
Safety criteria: number of symptomatic hypoglycemia episodes and number of severe hypoglycemic events
|
after 3 months of treatment with Galvus or placebo
|
Collaborators and Investigators
Investigators
- Principal Investigator: Sylvia FRANC, MD, CH SUd Francilien
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protease Inhibitors
- Dipeptidyl-Peptidase IV Inhibitors
- Insulin
- Insulin, Globin Zinc
- Metformin
- Vildagliptin
Other Study ID Numbers
- 2011-001813-14
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on Vildagliptin
-
Laboratorios Silanes S.A. de C.V.Recruiting
-
Novartis PharmaceuticalsCompletedType II Diabetes Mellitus | Congestive Heart FailureRussian Federation, Singapore, Italy, Czechia, Lithuania, Germany, Guatemala, India, Denmark, Estonia, Slovakia, Romania, Latvia, Greece, Poland
-
Novartis PharmaceuticalsCompletedType 2 Diabetes MellitusSpain, Poland, South Africa, Taiwan, Hong Kong, Norway, Italy, Bulgaria, Latvia, Lithuania, Germany, Turkey, Argentina, Israel, Korea, Republic of, Dominican Republic, Guatemala, Brazil, Colombia, Peru, Philippines, Russian Federation and more
-
NovartisCompleted
-
Novartis PharmaceuticalsCompletedDiabetes Mellitus, Type 2Switzerland, Germany
-
Novartis PharmaceuticalsCompletedDiabetes Mellitus, Type 2United States, Germany
-
Bio-innova Co., LtdNot yet recruiting
-
Radboud University Medical CenterCompletedType 2 Diabetes | Endothelial DysfunctionNetherlands
-
Novartis PharmaceuticalsCompletedDiabetes Mellitus, Type 2United States
-
NovartisCompletedDiabetes Mellitus, Type 2Germany, United States